small nucleolar RNA, C/D box 30Genealiases: RNU30 · U30
Q-omics provides the consensus-scored SNORD30 profile across patient tissues and cancer cell-line models. SNORD30 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SNORD30 is differentially expressed in 5, with the highest sampling consensus in COAD. Additionally, SNORD30 RNA expression shows 7,315 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight KIRC, COAD, and DLBC as cancer lineages where SNORD30 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORD30 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORD30 survival associations across molecular data types. SNORD30 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORD30 RNA expression–survival associations across cancer types. High SNORD30 expression shows unfavorable associations in KIRC, UVM, BRCA, ESCA, MESO and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SNORD30 RNA expression.
This table summarizes SNORD30 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SNORD30. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORD30 shows higher tumor expression in COAD, KICH, STAD, READ and LUSC. The COAD box plot shows higher SNORD30 RNA expression in tumor versus normal tissue (log2 FC = +1.577, t-test p < 0.001).
This table shows molecular features associated with SNORD30 in patient tissues and cancer cell lines. In patient samples, SNORD30 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
